AU2002227175A1 - Anti-tenascin monoclonal antibody therapy for lymphoma - Google Patents

Anti-tenascin monoclonal antibody therapy for lymphoma

Info

Publication number
AU2002227175A1
AU2002227175A1 AU2002227175A AU2002227175A AU2002227175A1 AU 2002227175 A1 AU2002227175 A1 AU 2002227175A1 AU 2002227175 A AU2002227175 A AU 2002227175A AU 2002227175 A AU2002227175 A AU 2002227175A AU 2002227175 A1 AU2002227175 A1 AU 2002227175A1
Authority
AU
Australia
Prior art keywords
lymphoma
monoclonal antibody
antibody therapy
tenascin monoclonal
tenascin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002227175A
Inventor
Darell D. Bigner
David Rizzieri
Michael Zalutsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU2002227175A1 publication Critical patent/AU2002227175A1/en
Abandoned legal-status Critical Current

Links

AU2002227175A 2000-12-21 2001-10-24 Anti-tenascin monoclonal antibody therapy for lymphoma Abandoned AU2002227175A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60/257,108 2000-12-21

Publications (1)

Publication Number Publication Date
AU2002227175A1 true AU2002227175A1 (en) 2002-07-08

Family

ID=

Similar Documents

Publication Publication Date Title
AU2002222112A1 (en) Hybrid antibodies
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
AU2002256895A1 (en) Anti-TRAIL-R antibodies
IL156030A0 (en) Humanized antibodies
IL155340A0 (en) HUMANIZED ANTI LYMPHOTOXIN-beta-RECEPTOR ANTIBODIES
AUPR395801A0 (en) Antibodies against cancer
AU2001234125A1 (en) Antibody library
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2001252599A1 (en) Remedies for cancer
AU2001290860A1 (en) Spas-1 cancer antigen
AU5441000A (en) Human monoclonal antibody
AU2001277711A1 (en) Remedies for cisplatin-tolerant cancer
AU1598801A (en) HGF-SF monoclonal antibody combinations
AU2002346581A1 (en) Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
AU2002351374A1 (en) Antibodies to treat cancer
AU2001294274A1 (en) Antibody inhibiting VPLF activity
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
AU2002216847A1 (en) Epitopes of pai-1
AU3283500A (en) Tumor-associated antigen
AU2002221132A1 (en) Novel antibody
AU5046700A (en) Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT
AU2002227175A1 (en) Anti-tenascin monoclonal antibody therapy for lymphoma
AU2001274860A1 (en) Process for reducing antibody response against xenografts
AU2001245781A1 (en) Cd18-binding antibodies inhibit stenosis-related disorders
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin